Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CT4D
|
|||
| Former ID |
DCL000730
|
|||
| Drug Name |
Brivaracetam
|
|||
| Synonyms |
Rikelta; UCB-34714; Brivaracetam (USAN/INN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Complex partial seizure [ICD-11: 8A68.0] | Approved | [1] | |
| Epilepsy [ICD-11: 8A60-8A68] | Phase 3 | [2], [3] | ||
| Pain [ICD-11: MG30-MG3Z] | Phase 3 | [2], [3] | ||
| Company |
UCB
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H20N2O2
|
|||
| Canonical SMILES |
CCCC1CC(=O)N(C1)C(CC)C(=O)N
|
|||
| InChI |
1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
|
|||
| InChIKey |
MSYKRHVOOPPJKU-BDAKNGLRSA-N
|
|||
| CAS Number |
CAS 357336-20-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:133013
|
|||
| ADReCS Drug ID | BADD_D00297 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Synaptic vesicle glycoprotein 2A (SV2A) | Target Info | Inhibitor | [4], [5] |
| KEGG Pathway | ECM-receptor interaction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. | |||
| REF 3 | Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. | |||
| REF 4 | Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39. | |||
| REF 5 | New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.